Pubblicazioni Scientifiche
Dermatologia03 lug 2019
Immunological methods for the diagnosis of oral mucosal diseases
Immunological methods, which have been widely used in autoimmune blistering diseases (AIBDs) of the oral mucosa, can also be adopted as auxiliary diagnostic tools in oral lichen planus (OLP) and discoid lupus erythematosus (DLE).
03 lug 2019
Premalignant and malignant oral mucosal lesions: Clinical and pathological findings.
Premalignant and malignant lesions of the oral cavity
03 lug 2019
British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS‐TEN overlap in children (0–12 years) and young people (13–17 years)
03 giu 2019
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis
Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects.
03 giu 2019
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients
Panniculitis and vitiligo-like lesions have been recently identified as rare cutaneous side effects of the combination of BRAF and MEK inhibitors, a standard of care in metastatic and locally advanced BRAF V600 mutated melanoma.
03 giu 2019
Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology
Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non‐neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society
29 mag 2019
The integration of dermoscopy and reflectance confocal microscopy improves the diagnosis of lentigo maligna.
The clinical diagnosis of lentigo maligna (LM)/lentigo maligna melanoma (LMM) often represents a challenge due to its overlapping features with benign lesions.
29 mag 2019
Androgens in women: Androgen-mediated skin disease and patient evaluation.
Androgens are produced throughout the body in steroid-producing organs, such as the adrenal glands and ovaries, and in other tissues, like the skin.
29 mag 2019
Androgens in women: Hormone-modulating therapies for skin disease
Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies
22 mag 2019
Platelet-rich plasma and its utility in the treatment of acne scars: A systematic review
The field of dermatology has seen numerous therapeutic innovations in the past decade, with platelet-rich plasma recently garnering significant interest in acne scarring.
22 mag 2019
Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? a systematic
Organ transplant recipients (OTR) have a higher risk of developing cutaneous squamous cell carcinoma (cSCC) compared to the immunocompetent population. Immunosuppression is often stated as a risk factor for metastasis. However, evidence for this is scarce. Objectives
22 mag 2019
Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives.
Psoriasis affects 2-4% of the world’s population
14 mag 2019
Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis
Aim of this observational study was to assess safety and efficacy of Certolizumab Pegol(CZP) in a real-life cohort of patients affected by psoriasis(PsO) and psoriatic arthritis(PsA), who had an inadequate response to previous systemic immunosuppressive treatments, with a follow-up of 24 weeks.
14 mag 2019
Ultrasound assessment of the keratolitic effect of a 50% urea anhydrous paste on psoriasis plaques: a prospective study
The keratolytic effect of urea is well-known, although the majority of the available studies rely on clinical observation only. The aim of this open trial was to evaluate, through clinical and ultrasound assessment, the efficacy and tolerability of a 50% urea anhydrous paste on hyperkeratotic psoriatic plaques
14 mag 2019
Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis
Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter
08 mag 2019
Objective evaluation of infantile hemangiomas response to propanolol treatment using a 3D imaging system
Infantile hemangioma (IH) is the most common benign vascular tumor of infancy.
08 mag 2019
Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate to severe plaque‐type psoriasis
Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects.
06 mag 2019
Scienziati cinesi scoprono nuovo gene legato a comparsa acne
Un gruppo di scienziati cinesi ha scoperto un nuovo gene legato alla comparsa dell'acne.
06 mag 2019
Primary pediatric cutaneous mucinoses
Primary cutaneous mucinoses are a heterogeneous group of diseases characterized by the abnormal deposition of glycosamminoglycans (mucin) in the skin as the main histopathological clue resulting in distinctive clinical presentations.
29 apr 2019
The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria
Diagnostic criteria are used to identify a patient having a disease in a clinical setting, whereas classification criteria create a well‐defined population for research purposes. The diagnosis and classification of amyopathic dermatomyositis (ADM) have not been recognized by most existing criteria for idiopathic inflammatory myopathies (IIMs). To address this, several criteria were proposed to define ADM either as a distinct disease entity or as a subset of the spectrum of IIMs.